Jane Tomimori
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jane Tomimori has a total of 94 co-authors. Here are the top co-authors by number of shared publications:
- Marília Marufuji Ogawa
Universidade Federal de São Paulo, Brazil
8 shared publications - Milvia Maria Simões e Silva Enokihara
Department of Pathology, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, SP, Brazil
6 shared publications - Marcos Cesar Florian
Department of Dermatology, Paulista Medical School, Federal University of Sao Paulo, Sao Paulo, Brazil
3 shared publications - Adriana Maria Porro
Department of Dermatology, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, SP, Brazil
2 shared publications - Anamaria da Silva Facina
Departamento de Dermatologia, Hospital São Paulo, Escola Paulista de Medicina Universidade Federal de São Paulo São Paulo Brazil
2 shared publications - Camila Arai Seque
Department of Dermatology, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, SP, Brazil
2 shared publications
Latest Publications
- 28 October 2026
- Published by Wolters Kluwer Health in Dermatologic Surgery
Survival Outcomes of Patients With Melanoma Treated With Mohs Micrographic Surgery: A Systematic Review and Meta-Analysis
BACKGROUND: Wide local excision (WLE) is the standard treatment for cutaneous melanoma. Mohs micrographic surgery (MMS), a tissue-sparing technique with comprehensive margin assessment, is an alternative in selected cases. With increased MMS use, its optimal scope for melanoma treatment remains under discussion due to the complexity of frozen-section interpretation and lack of randomized trials evaluating long-term outcomes. OBJECTIVE: To compare survival between MMS and WLE for melanoma. METHODS/MATERIALS: PubMed, Embase, and Cochrane databases were systematically searched for comparative studies reporting overall or disease-specific survival. Outcomes were compared using adjusted hazard ratios (95% confidence intervals). Heterogeneity was assessed with I 2 . RESULTS: Thirteen studies with more than 500,000 individuals were included in the statistical analysis. Long-term overall (HR = 0.93; 95% CI = 0.87–0.99; p -value = .03) and disease-specific survival (HR = 0.63; 95% CI = 0.56–0.72; p -value<.00001) were significantly higher with MMS versus WLE. Overall survival benefit was mainly driven by head/neck melanoma (HR = 0.92; 95% CI = 0.86–0.99; p -value = .03), particularly invasive disease (HR = 0.91; 95% CI = 0.84–0.99; p -value = .03). Lentigo maligna subtype also showed higher overall survival with MMS (HR = 0.89; 95% CI = 0.82–0.97; p -value = .006). No difference was observed in 5-year overall or disease-specific survival (HR = 0.92; 95% CI = 0.80–1.05; p -value = .12 and HR = 0.87; 95% CI = 0.56–1.34; p -value = .52; respectively). CONCLUSION: MMS was consistently associated with survival similar or superior to WLE, supporting its expanding role in melanoma management.
- 28 October 2026
- Published by Wolters Kluwer Health in Dermatologic Surgery
Survival Outcomes of Patients With Melanoma Treated With Mohs Micrographic Surgery: A Systematic Review and Meta-Analysis
BACKGROUND: Wide local excision (WLE) is the standard treatment for cutaneous melanoma. Mohs micrographic surgery (MMS), a tissue-sparing technique with comprehensive margin assessment, is an alternative in selected cases. With increased MMS use, its optimal scope for melanoma treatment remains under discussion due to the complexity of frozen-section interpretation and lack of randomized trials evaluating long-term outcomes. OBJECTIVE: To compare survival between MMS and WLE for melanoma. METHODS/MATERIALS: PubMed, Embase, and Cochrane databases were systematically searched for comparative studies reporting overall or disease-specific survival. Outcomes were compared using adjusted hazard ratios (95% confidence intervals). Heterogeneity was assessed with I 2 . RESULTS: Thirteen studies with more than 500,000 individuals were included in the statistical analysis. Long-term overall (HR = 0.93; 95% CI = 0.87–0.99; p -value = .03) and disease-specific survival (HR = 0.63; 95% CI = 0.56–0.72; p -value<.00001) were significantly higher with MMS versus WLE. Overall survival benefit was mainly driven by head/neck melanoma (HR = 0.92; 95% CI = 0.86–0.99; p -value = .03), particularly invasive disease (HR = 0.91; 95% CI = 0.84–0.99; p -value = .03). Lentigo maligna subtype also showed higher overall survival with MMS (HR = 0.89; 95% CI = 0.82–0.97; p -value = .006). No difference was observed in 5-year overall or disease-specific survival (HR = 0.92; 95% CI = 0.80–1.05; p -value = .12 and HR = 0.87; 95% CI = 0.56–1.34; p -value = .52; respectively). CONCLUSION: MMS was consistently associated with survival similar or superior to WLE, supporting its expanding role in melanoma management.
- Open Access
- 3 August 2026
- Published by Elsevier in Anais Brasileiros de Dermatologia
- Vol. 101 (5) , 501447
The new metrics of Anais Brasileiros de Dermatologia
- 3 August 2026
- Published by Elsevier in Anais Brasileiros de Dermatologia
- Vol. 101 (5) , 501447
Open AccessThe new metrics of Anais Brasileiros de Dermatologia
- Open Access
- 1 December 2023
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Nephrology
- Vol. 45 (4) , 480-487
Uso do sirolimo como terapia adjuvante para receptores de transplante renal com carcinoma espinocelular cutâneo de alto risco: um estudo prospectivo controlado não randomizado
RESUMO Introdução: Pesquisas anteriores demonstraram benefícios da conversão tardia para inibidores de mTOR contra carcinomas espinocelulares cutâneos (CECs) em receptores de transplante renal (RTR), apesar da baixa tolerabilidade. Este estudo investigou se a conversão gradual para monoterapia com sirolimo sem dose de ataque modificou o curso da doença com melhor tolerabilidade. Métodos: Esse estudo prospectivo exploratório incluiu RTR não sensibilizados com mais de 12 meses pós-transplante, uso contínuo de terapia imunossupressora baseado em inibidor de calcineurina (CNI) associado a micofenolato de sódio ou azatioprina, com lesões de CECs de mau prognóstico. Comparou-se densidades de incidência de CECs de alto risco durante 3 anos após conversão para monoterapia com sirolimo à um grupo não randomizado com CECs classificados conforme os mesmos critérios de gravidade do grupo sirolimo, mas inadequado/não disposto à conversão. Resultados: Foram incluídos 44 pacientes (83% homens, idade média 60 ± 9,7 anos, 62% com fototipo de pele II, tempo médio pós-transplante 9 ± 5,7 anos). 25 pacientes foram convertidos para SRL e 19 indivíduos mantidos em CNI. Foi observado tendência de diminuição da densidade de incidência de todos CECs no grupo SRL e de aumento no grupo CNI (1,49 a 1,00 lesões/paciente-ano; 1,74 a 2,08 lesões/paciente-ano; p = 0,141). A densidade de incidência de lesões moderadamente diferenciadas diminuiu significativamente no grupo SRL enquanto aumentou significativamente no grupo CNI (0,31 a 0,11 lesões/paciente-ano; 0,25 a 0,62 lesões/paciente-ano; p = 0,001). No grupo SRL não houve descontinuação do sirolimo, nenhum episódio de rejeição aguda e nenhuma formação de DSA de novo. Função renal permaneceu estável. Conclusões: Esse estudo sugere que a monoterapia com sirolimo pode ser útil como terapia adjuvante de CECs de alto risco em RTR. A estratégia de conversão usada foi bem tolerada e segura em relação aos principais desfechos do transplante a médio prazo.
- 1 December 2023
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Nephrology
- Vol. 45 (4) , 480-487
Open AccessUso do sirolimo como terapia adjuvante para receptores de transplante renal com carcinoma espinocelular cutâneo de alto risco: um estudo prospectivo controlado não randomizado
RESUMO Introdução: Pesquisas anteriores demonstraram benefícios da conversão tardia para inibidores de mTOR contra carcinomas espinocelulares cutâneos (CECs) em receptores de transplante renal (RTR), apesar da baixa tolerabilidade. Este estudo investigou se a conversão gradual para monoterapia com sirolimo sem dose de ataque modificou o curso da doença com melhor tolerabilidade. Métodos: Esse estudo prospectivo exploratório incluiu RTR não sensibilizados com mais de 12 meses pós-transplante, uso contínuo de terapia imunossupressora baseado em inibidor de calcineurina (CNI) associado a micofenolato de sódio ou azatioprina, com lesões de CECs de mau prognóstico. Comparou-se densidades de incidência de CECs de alto risco durante 3 anos após conversão para monoterapia com sirolimo à um grupo não randomizado com CECs classificados conforme os mesmos critérios de gravidade do grupo sirolimo, mas inadequado/não disposto à conversão. Resultados: Foram incluídos 44 pacientes (83% homens, idade média 60 ± 9,7 anos, 62% com fototipo de pele II, tempo médio pós-transplante 9 ± 5,7 anos). 25 pacientes foram convertidos para SRL e 19 indivíduos mantidos em CNI. Foi observado tendência de diminuição da densidade de incidência de todos CECs no grupo SRL e de aumento no grupo CNI (1,49 a 1,00 lesões/paciente-ano; 1,74 a 2,08 lesões/paciente-ano; p = 0,141). A densidade de incidência de lesões moderadamente diferenciadas diminuiu significativamente no grupo SRL enquanto aumentou significativamente no grupo CNI (0,31 a 0,11 lesões/paciente-ano; 0,25 a 0,62 lesões/paciente-ano; p = 0,001). No grupo SRL não houve descontinuação do sirolimo, nenhum episódio de rejeição aguda e nenhuma formação de DSA de novo. Função renal permaneceu estável. Conclusões: Esse estudo sugere que a monoterapia com sirolimo pode ser útil como terapia adjuvante de CECs de alto risco em RTR. A estratégia de conversão usada foi bem tolerada e segura em relação aos principais desfechos do transplante a médio prazo.
- Open Access
- 1 December 2023
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Nephrology
- Vol. 45 (4) , 480-487
Use of sirolimus as an adjuvant therapy for kidney transplant recipients with high-risk cutaneous squamous cell carcinomas: a prospective non-randomized controlled study
Introduction: Previous research demonstrated benefits of late conversion to mTOR inhibitors against cutaneous squamous cell carcinomas (cSCC) in kidney transplant recipients (KTR), despite of poor tolerability. This study investigated whether stepwise conversion to sirolimus monotherapy without an attack dose modified the course of disease with improved tolerability. Methods: This prospective exploratory study included non-sensitized KTR with more than 12-months post-transplant, on continuous use of calcineurin inhibitors (CNI)-based therapy, and with poor-prognosis cSCC lesions. Incidence densities of high-risk cSCC over 3-years after conversion to sirolimus-monotherapy were compared to a non-randomized group with high-risk cSCC but unsuitable/not willing for conversion. Results: Forty-four patients were included (83% male, mean age 60 ± 9.7years, 62% with skin type II, mean time after transplantation 9 ± 5.7years). There were 25 patients converted to SRL and 19 individuals kept on CNI. There was a tendency of decreasing density of incidence of all cSCC in the SRL group and increasing in the CNI group (1.49 to 1.00 lesions/patient-year and 1.74 to 2.08 lesions/patient-year, p = 0.141). The density incidence of moderately differentiated decreased significantly in the SRL group while increasing significantly in the CNI group (0.31 to 0.11 lesions/patient-year and 0.25 to 0.62 lesions/patient-year, p = 0.001). In the SRL group, there were no sirolimus discontinuations, no acute rejection episodes, and no de novo DSA formation. Renal function remained stable. Conclusions: This study suggests that sirolimus monotherapy may be useful as adjuvant therapy of high-risk cSCC in kidney transplant recipients. The conversion strategy used was well tolerated and safe regarding key mid-term transplant outcomes.
- 1 December 2023
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Nephrology
- Vol. 45 (4) , 480-487
Open AccessUse of sirolimus as an adjuvant therapy for kidney transplant recipients with high-risk cutaneous squamous cell carcinomas: a prospective non-randomized controlled study
Introduction: Previous research demonstrated benefits of late conversion to mTOR inhibitors against cutaneous squamous cell carcinomas (cSCC) in kidney transplant recipients (KTR), despite of poor tolerability. This study investigated whether stepwise conversion to sirolimus monotherapy without an attack dose modified the course of disease with improved tolerability. Methods: This prospective exploratory study included non-sensitized KTR with more than 12-months post-transplant, on continuous use of calcineurin inhibitors (CNI)-based therapy, and with poor-prognosis cSCC lesions. Incidence densities of high-risk cSCC over 3-years after conversion to sirolimus-monotherapy were compared to a non-randomized group with high-risk cSCC but unsuitable/not willing for conversion. Results: Forty-four patients were included (83% male, mean age 60 ± 9.7years, 62% with skin type II, mean time after transplantation 9 ± 5.7years). There were 25 patients converted to SRL and 19 individuals kept on CNI. There was a tendency of decreasing density of incidence of all cSCC in the SRL group and increasing in the CNI group (1.49 to 1.00 lesions/patient-year and 1.74 to 2.08 lesions/patient-year, p = 0.141). The density incidence of moderately differentiated decreased significantly in the SRL group while increasing significantly in the CNI group (0.31 to 0.11 lesions/patient-year and 0.25 to 0.62 lesions/patient-year, p = 0.001). In the SRL group, there were no sirolimus discontinuations, no acute rejection episodes, and no de novo DSA formation. Renal function remained stable. Conclusions: This study suggests that sirolimus monotherapy may be useful as adjuvant therapy of high-risk cSCC in kidney transplant recipients. The conversion strategy used was well tolerated and safe regarding key mid-term transplant outcomes.
Onychomycosis in immunocompromised population: Phenotypic and molecular identification
Onychomycosis is common among immunosuppressed individuals. Renal transplant recipients (RTR) and lupus nephritis (LN) patients are submitted to corticosteroid and other immunosuppressive therapy; and diabetes mellitus (DM) patients are intrinsically immunocompromised.Objectives: The aim of this study was to characterise and identify fungal infections on the nails (feet and hands) in immunocompromised patients.Methods: The clinical material, nail scales (foot and/or hand), was collected from 47 RTR, 66 LN, 67 DM, and 78 immunocompetent individuals (control group). Phenotypic and molecular analyses were performed.Results: A total of 258 patients were examined. There was a female predominance, except in the RTR. The average age was 52 years old. Lateral distal subungual onychomycosis (OSDL) (75.2%), mainly affecting the hallux nail, was frequent. The predominance of dermatophyte on toenails and Candida species on fingernails was statistically significant. A higher frequency of fingernail involvement in LN and DM, and for LN, the difference was significant (p = .0456). Infections by Candida spp. were more frequent in DM. Using molecular methods, 87.2% of diagnoses were confirmed, identifying fungal agents at the species level. Dermatophytes, Trichophyton rubrum and Trichophyton interdigitale and the species of Candida, C. parapsilosis and C. albicans, were the most frequent fungal agents.Conclusions: Molecular techniques (sequencing of ITS regions of rDNA) offer greater accuracy, although there is no difference, regarding the detection. Clinical presentation and fungal species may differ somewhat from the general population. Immunosuppression did not increase fungal detection positivity.
Onychomycosis in immunocompromised population: Phenotypic and molecular identification
Onychomycosis is common among immunosuppressed individuals. Renal transplant recipients (RTR) and lupus nephritis (LN) patients are submitted to corticosteroid and other immunosuppressive therapy; and diabetes mellitus (DM) patients are intrinsically immunocompromised.Objectives: The aim of this study was to characterise and identify fungal infections on the nails (feet and hands) in immunocompromised patients.Methods: The clinical material, nail scales (foot and/or hand), was collected from 47 RTR, 66 LN, 67 DM, and 78 immunocompetent individuals (control group). Phenotypic and molecular analyses were performed.Results: A total of 258 patients were examined. There was a female predominance, except in the RTR. The average age was 52 years old. Lateral distal subungual onychomycosis (OSDL) (75.2%), mainly affecting the hallux nail, was frequent. The predominance of dermatophyte on toenails and Candida species on fingernails was statistically significant. A higher frequency of fingernail involvement in LN and DM, and for LN, the difference was significant (p = .0456). Infections by Candida spp. were more frequent in DM. Using molecular methods, 87.2% of diagnoses were confirmed, identifying fungal agents at the species level. Dermatophytes, Trichophyton rubrum and Trichophyton interdigitale and the species of Candida, C. parapsilosis and C. albicans, were the most frequent fungal agents.Conclusions: Molecular techniques (sequencing of ITS regions of rDNA) offer greater accuracy, although there is no difference, regarding the detection. Clinical presentation and fungal species may differ somewhat from the general population. Immunosuppression did not increase fungal detection positivity.
- 15 November 2022
- Published by Springer Nature
- p. 115-141
Mycobacterial Diseases
- 15 November 2022
- Published by Springer Nature
- p. 409-435
Other Rare Cancers
- Open Access
- 2 November 2022
- Published by Elsevier in Medical Mycology Case Reports
- Vol. 38, 41-43
Cutaneous chromoblastomycosis mimicking melanoma in a renal transplant recipient
- 2 November 2022
- Published by Elsevier in Medical Mycology Case Reports
- Vol. 38, 41-43
Open AccessCutaneous chromoblastomycosis mimicking melanoma in a renal transplant recipient
- 8 September 2022
- Published by Wiley in International Journal of Dermatology
- Vol. 62 (1) , E24-+
Lupus tumidus in kidney transplant recipient: a case of an autoimmune disease in an immunosuppressed patient
- 8 September 2022
- Published by Wiley in International Journal of Dermatology
- Vol. 62 (1) , E24-+
Lupus tumidus in kidney transplant recipient: a case of an autoimmune disease in an immunosuppressed patient
- 3 February 2022
- Published by Wiley in International Journal of Dermatology
- Vol. 61 (9) , E346-E348
Aspergillus fumigatus as an agent of secondary cutaneous aspergillosis in a renal transplant recipient: a case report
- 3 February 2022
- Published by Wiley in International Journal of Dermatology
- Vol. 61 (9) , E346-E348
Aspergillus fumigatus as an agent of secondary cutaneous aspergillosis in a renal transplant recipient: a case report